Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.53%
SPX
+0.32%
IXIC
+0.25%
FTSE
-0.13%
N225
-0.04%
AXJO
0.00%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

About

What does NTLA do?
Intellia Therapeutics, based in Cambridge, Massachusetts, develops CRISPR/Cas9-based therapeutics for high unmet medical needs, including treatments for ATTR amyloidosis and hereditary angioedema. The company went public on May 6, 2016.
Sector
💻 Health Care
IPO
CEO
Employees
Headquarters
Massachusetts, USA
Website
http://www.intelliatx.com

Recently from Cashu

publisher logo
Cashu

Intellia Therapeutics and KalVista: Advancements in Hereditary Angioedema Treatment with KALV Ekterly

6 days ago
publisher logo
Cashu

Intellia Therapeutics: KalVista Pharmaceuticals Launches KALV Ekterly for Hereditary Angioedema Treatment

8 days ago
publisher logo
Cashu

Intellia Therapeutics Under Ethical Scrutiny Amid FDA Review of Genetic Engineering Trials

23 days ago

Key Stats

Market Cap
1.19B
Dividend Yield
0.00%
P/E Ratio
-2.26
EPS
-5.24
Revenue
57.88M
Avg. Volume
3.16M
Stocks
Health Care
ntla
Intellia Therapeutics
NTLA
+0.49 (+4.27%)
11.97
USD
At close at Jul 16, 20:41 UTC
Summary
News
Signals
Benchmarks
Financials